Literature DB >> 9761751

Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development.

L M Montuenga1, J Zhou, I Avis, M Vos, A Martinez, F Cuttitta, A M Treston, M Sunday, J L Mulshine.   

Abstract

Recent reports have demostrated a link between expression of members of the family of heterogeneous nuclear ribonucleoproteins (hnRNPs) and cancer. Overexpression of hnRNP A2/B1 correlated with the eventual development of lung cancer in three different clinical cohorts. We have studied the expression of hnRNP A2/B1 messenger RNA (mRNA) and protein during mammalian development. The expression of hnRNP A2/B1 mRNA and protein are parallel but change dynamically during critical periods in mouse pulmonary development. hnRNP A2/B1 is first detected in the lung in the early pseudoglandular period, peaks at the beginning of the canalicular period, and remains high during the saccular (alveolar) period. In mouse and rat, hnRNP A2/B1 expression is first evident in the earliest lung buds. As lung development progresses, the cuboidal epithelial cells of the distal primitive alveoli show high levels of the ribonucleoprotein, which is almost undetectable in the proximal conducting airways. The expression of hnRNP A2/ B1 is restricted in mature lung. Similar dynamic pattern of expression through lung development was also found in rat and human lung. Upregulated expression of hnRNP A2/B1 at critical periods of lung development was comparable to the level of expression found in lung cancers and preneoplastic lesions and is consistent with hnRNP A2/B1 overexpression playing an oncodevelopmental role.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761751     DOI: 10.1165/ajrcmb.19.4.3185

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  9 in total

1.  Characterization of the mRNA ligands bound by the RNA binding protein hnRNP A2 utilizing a novel in vivo technique.

Authors:  S A Brooks; W F Rigby
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

Review 2.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

3.  Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis.

Authors:  M Lu; R M Nakamura; E D Dent; J Y Zhang; F C Nielsen; J Christiansen; E K Chan; E M Tan
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

4.  Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.

Authors:  Huaqing Cui; Feng Wu; Yanling Sun; Guocai Fan; Qingming Wang
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

5.  A proteomic comparison of immature and mature mouse gonadotrophs reveals novel differentially expressed nuclear proteins that regulate gonadotropin gene transcription and RNA splicing.

Authors:  Jiajun Feng; Mark A Lawson; Philippa Melamed
Journal:  Biol Reprod       Date:  2008-05-14       Impact factor: 4.285

6.  HnRNP A2/B1 proteins in nontumorous alveolar cells.

Authors:  H Satoh; H Ishikawa; H Kamma; Y T Yamashita; K Sekizawa
Journal:  Lung       Date:  2003       Impact factor: 2.584

7.  Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.

Authors:  Georgios Boukakis; Meropi Patrinou-Georgoula; Maria Lekarakou; Christos Valavanis; Apostolia Guialis
Journal:  BMC Cancer       Date:  2010-08-17       Impact factor: 4.430

Review 8.  Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets.

Authors:  Ya Lu; Xinyue Wang; Quan Gu; Juan Wang; Ying Sui; Jianzhong Wu; Jifeng Feng
Journal:  Cell Death Discov       Date:  2022-07-25

9.  Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.

Authors:  Alessio Di Luca; Michael Henry; Paula Meleady; Robert O'Connor
Journal:  Daru       Date:  2015-08-04       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.